title: Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial.
abstract: OBJECTIVE
  Evaluation of the long-term safety and efficacy of second-generation everolimus-eluting stents (EES) versus first-generation sirolimus-eluting stents (SES) in acute myocardial infarction (AMI) patients.
  
  
  RESULTS
  Six hundred and twenty-five patients were randomised (2:1) to EES or SES in the multicentre XAMI (XienceV stent vs. Cypher stent in Primary PCI for Acute Myocardial Infarction) trial. The primary endpoint was cardiac death, non-fatal AMI or any target vessel revascularisation (TVR) at one year, with a planned follow-up of three years. At three-year follow-up, the primary endpoint was 8.0% for EES and 10.5% for SES (p=0.30). Cardiac death was low and comparable in both groups (EES: 2.5% versus SES: 2.7%; p=0.86), as was definite/probable stent thrombosis (EES: 2.3% versus SES 3.2%; p=0.60).
  
  
  CONCLUSIONS
  The event rate at three years in this all-comer, randomised, multicentre AMI trial was low, including stent thrombosis, with no significant difference between first- and second-generation DES. Registration of trial:http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1123 Candidate number: 2869; NTR number: NTR1123.
authors.affiliation: Medical Center Leeuwarden, Leeuwarden, The Netherlands.
authors.forename: Sjoerd H
authors.initials: SH
authors.lastname: Hofma
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Jan
authors.initials: J
authors.lastname: Brouwer
authors.forename: Matthijs A
authors.initials: MA
authors.lastname: Velders
authors.forename: Arnoud W J
authors.initials: AW
authors.lastname: van 't Hof
authors.forename: Michel
authors.initials: M
authors.lastname: Queré
authors.forename: Cornelis Jan
authors.initials: CJ
authors.lastname: de Vries
authors.forename: Adrianus J
authors.initials: AJ
authors.lastname: van Boven
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation; D012086:Reoperation; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus